ONON inventory forecast 2025 refers back to the predicted efficiency of Onconova Therapeutics, Inc. (ONON) inventory over the following few years. It can be crucial for buyers to think about inventory forecasts as they will present invaluable insights into the potential progress and profitability of an organization.
ONON is a clinical-stage biopharmaceutical firm centered on discovering and creating novel most cancers therapies. The corporate’s lead product candidate, rigosertib, is a small molecule that targets a number of signaling pathways concerned in most cancers progress and survival. Rigosertib is at present being evaluated in a number of scientific trials for the remedy of assorted forms of most cancers, together with lung most cancers, breast most cancers, and pancreatic most cancers.
